RxDoctor Payments Data

Whitney Nimmo-Olsen

Family · Macclenny, FLNPI 1659770121

Payments from drug & device makers

$701in general payments, 2019–2025

Across 40 payments — averaging $17.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$183
  • AbbVie$113
  • Idorsia Pharmaceuticals US Inc$83
  • Astellas Pharma US Inc$65
  • Novo Nordisk$61
  • GSK$46
  • plus $151 from 6 others

What the payments were for

  • Food & beverage$701100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$701 in reported general payments places this provider in the 60th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$101,358
Medicare patients
203
Services billed
1,920

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide94$123,816
EliquisApixaban75$60,351
OzempicSemaglutide32$54,028
FarxigaDapagliflozin Propanediol59$50,738
JanuviaSitagliptin Phosphate26$35,980
JardianceEmpagliflozin27$35,182
LinzessLinaclotide52$34,193
Breztri AerosphereBudesonide/Glycopyr/Formoterol41$29,628
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$28,190
Tresiba Flextouch U-100Insulin Degludec21$25,702
XareltoRivaroxaban24$15,876
MyrbetriqMirabegron24$15,866
LyricaPregabalin13$12,007
SymbicortBudesonide/Formoterol Fumarate39$10,110
Spiriva RespimatTiotropium Bromide17$8,955

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$17$123,81694 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$183$90,476139 claims
PfizerEliquis, Lyrica$38$72,35888 claims
Novo NordiskOzempic$61$54,02832 claims
AbbVieLinzess, Synthroid, Combigan$113$39,17693 claims
GSKTrelegy Ellipta, Breo Ellipta$46$34,27750 claims
Astellas Pharma US IncMyrbetriq$65$15,86624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 14,618 family providers in Florida.

Other family in Macclenny

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →